Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria

被引:59
作者
Adoga, Moses P. [1 ]
Banwat, Edmund B. [2 ]
Forbi, Joseph C. [1 ]
Nimzing, Lohya [2 ]
Pam, Christopher R. [1 ]
Gyar, Silas D. [4 ]
Agabi, Yusuf A. [3 ]
Agwale, Simon M. [1 ]
机构
[1] Innovat Biotech Ltd, Dept Virol, GRA, Keffi, Nasarawa State, Nigeria
[2] Univ Jos, Fac Med Sci, Dept Med Microbiol, Jos, Nigeria
[3] Univ Jos, Fac Nat Sci, Dept Microbiol, Jos, Nigeria
[4] Nasarawa State Univ, Fac Nat & Appl Sci, Microbiol Unit, Dept Biol Sci, Keffi, Nigeria
关键词
HIV; HBV; HCV; co-infection; risk factors; HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTING DRUG-USERS; HIV; INFECTION; HCV; EPIDEMIOLOGY; POPULATION; SYPHILIS;
D O I
10.3855/jidc.472
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Background: Published data on HIV, HBV, and HCV in correctional facilities in Nigeria is scarce. We set out to establish the seroprevalence, co-infection, and risk factors for these infections for the first time among prison inmates in Nasarawa State, Nigeria. Methodology: In a cross-sectional study conducted between April and May, 2007, blood samples were collected from 300 male prisoners of a mean age of 29.2 years, in the state's four medium-security prisons (overall population: 587). Prior to the study, ethical clearance and informed consent were obtained and structured questionnaires were administered. Samples were analyzed for HIV, HBsAg, and HCV using anti-HIV 1+ 2-EIA-avicenna, Shantest (TM)-HBsAg ELISA, and anti-HCV-EIA-avicenna, respectively. Specimens initially reactive for HIV were retested with vironostika microelisa. Data were analyzed using SPSS version 13.0. P values <= 0.05 were considered significant. Results: Of the 300 subjects, 54 (18.0 %), 69 (23.0 %), and 37 (12.3 %) tested positive for HIV, HBV, and HCV, respectively. Co-infections were eight (2.7 %) for HIV/HBV and two (0.7 %) for HBV/HCV. Those aged 21-26 years were more likely to be infected with HIV and HBV, while those aged 33-38 years had the highest HCV infection. Associated risk factors included duration in prison, previous incarceration (for HIV, HBV and HCV), intra-prison anal sex, multiple sex partners (for HIV and HBV), ignorance of transmission modes, blood transfusion, and alcohol consumption (for HBV and HCV). No inmate injected drugs. Conclusions: The overall outcome represents the need for prison-focused intervention initiatives in Nigeria. Injected drug use is an unlikely major transmission mode among Nigerian inmates.
引用
收藏
页码:539 / 547
页数:9
相关论文
共 35 条
[1]
Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawan and Accra, Ghana [J].
Adjei, AA ;
Armah, HB ;
Gbagbo, F ;
Ampofo, WK ;
Quaye, IKE ;
Hesse, IFA ;
Mensah, G .
JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (05) :593-597
[2]
Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes [J].
Agwale, SM ;
Tanimoto, L ;
Womack, C ;
Odama, L ;
Leung, K ;
Duey, D ;
Negedu-Momoh, R ;
Audu, I ;
Mohammed, SB ;
Inyang, U ;
Graham, B ;
Ziermann, R .
JOURNAL OF CLINICAL VIROLOGY, 2004, 31 :S3-S6
[3]
American Thoracic Society, 2003, MMWR Recomm Rep, V52, P1
[4]
Baba MM, 2000, NIGER J MED, V9, P10
[5]
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy [J].
Babudieri, S ;
Longo, B ;
Sarmati, L ;
Starnini, G ;
Dori, L ;
Suligoi, B ;
Carbonara, S ;
Monarca, R ;
Quercia, G ;
Florenzano, G ;
Novati, S ;
Sardu, A ;
Iovinella, V ;
Casti, A ;
Romano, A ;
Uccella, I ;
Maida, I ;
Brunetti, B ;
Mura, MS ;
Andreoni, M ;
Rezza, G .
JOURNAL OF MEDICAL VIROLOGY, 2005, 76 (03) :311-317
[6]
Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison [J].
Burattini, MN ;
Massad, E ;
Rozman, M ;
Azevedo, RS ;
Carvalho, HB .
REVISTA DE SAUDE PUBLICA, 2000, 34 (05) :431-436
[7]
Hepatitis B and C in New South Wales prisons: Prevalence and risk factors [J].
Butler, TG ;
Dolan, KA ;
Ferson, MJ ;
McGuinness, LM ;
Brown, PR ;
Robertson, PW .
MEDICAL JOURNAL OF AUSTRALIA, 1997, 166 (03) :127-130
[8]
Butler T, 2007, AUST NZ J PUBL HEAL, V31, P44, DOI 10.1111/j.1753-6405.2007.00009.x
[9]
CDC, 2007, EP PREV HEP
[10]
American Medical Association, 2001, MMWR Recomm Rep, V50, P1